Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.74 ▼ -0.07
(-0.79%)
MKT CAP: $9.26B • VOL: 7.15M
52W L $2 52W H $12
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$7
MEDIAN
$10
MEAN
$10
HIGH
$12
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IBRX TAPE
IBRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $10.58 | $10.05 | 2025-02-14 | $7.95 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $11.01 | $10.31 | 2025-02-06 | $8.22 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $9.96 | $9.61 | 2025-01-29 | $8.39 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $8.91 | — | 2025-01-17 | $8.57 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $7.69 | $8.30 | 2025-01-09 | $7.78 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $10.40 | $9.09 | 2024-12-18 | $7.60 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $8.48 | $8.83 | 2024-12-04 | $8.13 | -4.3% | 48% | C |